Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01), FiscalAI reports.
Zentalis Pharmaceuticals Price Performance
Shares of ZNTL stock opened at $4.28 on Wednesday. The stock has a market cap of $304.69 million, a P/E ratio of -2.25 and a beta of 1.99. The company has a fifty day moving average price of $3.40 and a two-hundred day moving average price of $2.45. Zentalis Pharmaceuticals has a one year low of $1.13 and a one year high of $6.95.
Wall Street Analysts Forecast Growth
ZNTL has been the topic of a number of research reports. Guggenheim boosted their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. Finally, Wall Street Zen downgraded Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $5.83.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. Invesco Ltd. raised its holdings in shares of Zentalis Pharmaceuticals by 8.6% in the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after purchasing an additional 14,961 shares during the period. XTX Topco Ltd grew its holdings in Zentalis Pharmaceuticals by 5.1% during the fourth quarter. XTX Topco Ltd now owns 576,707 shares of the company’s stock worth $779,000 after purchasing an additional 28,078 shares during the period. Quadrature Capital Ltd grew its holdings in Zentalis Pharmaceuticals by 126.8% during the fourth quarter. Quadrature Capital Ltd now owns 137,568 shares of the company’s stock worth $186,000 after purchasing an additional 76,917 shares during the period. Opaleye Management Inc. increased its position in Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after buying an additional 1,084,356 shares during the last quarter. Finally, ADAR1 Capital Management LLC raised its stake in Zentalis Pharmaceuticals by 60.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock valued at $108,000 after buying an additional 30,000 shares during the period.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Featured Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
